Total Health

 

Total Health is the largest provider of free cancer care resources for people who are treating or living with cancer. Our programs arm cancer care teams with the latest research and strategies to improve patient outcomes.

For more info visit our website at Total Health.

 

Boston
13:52

2020 ASCO Virtual Direct™ Highlights

Targeting Exon 20 Insertions in NSCLC: Anti-Tumor Activity With T-Dxd in HER2m Disease, Assessing Efficacy of Treatment Options in EGFRm Disease

FEATURING Ibiayi Dagogo-Jack
  • 318 views
  • January 28, 2021
  • 3
06:59

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Cancer Survivorship: Recent Statistics and Key Points from NCI Framework. What Are the Rates of Underdiagnosis and Undertreatment and What Is the Risk for Childhood Cancer Survivors?

FEATURING Larissa Nekhlyudov
  • 9 views
  • September 18, 2020
10:56

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on PEACE/YOCAS Studies: What Are the Limitations and Strengths in Acupuncture for Chronic Pain? Do Yoga or Cognitive Behavioral Therapy for Insomnia (CBT-I) Affect QoL in Cancer Patients?

FEATURING Larissa Nekhlyudov
  • 13 views
  • September 18, 2020
13:25

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Geriatric Assessment (GA) Intervention in Older Patients with Advanced Cancer: What Are the Benefits When it Comes to Toxicity/Mortality? Could This Be a New SoC?

FEATURING Larissa Nekhlyudov
  • 3 views
  • September 18, 2020
13:07

2020 ASCO Virtual Direct™ Highlights

ASCO 2020 H&N Cancers Update: Post-Operative CRT in High-Risk Patients with SCC - What Is the Optimal Dose of Cisplatin? When Should We Use IO vs. Chemo/Cetuximab?

FEATURING Jochen Lorch
  • 11 views
  • September 17, 2020
10:13

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Thyroid Cancers: Can the Addition of Pembro Increase Lenvatinib Efficacy? Is the Combination of Targeted Therapy + Atezo Safe? Does Targeted + IO Lead to Improved OS?

FEATURING Jochen Lorch
  • 16 views
  • September 17, 2020
06:34

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on FDA Approved Selpercatinib in RET-Driven Thyroid Cancers: What Are the Benefits and AE? Is There Cross-Resistance with Selpercatinib and Pralsetinib?

FEATURING Jochen Lorch
  • 16 views
  • September 17, 2020
11:33

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Locoregional CRC: 3 vs. 6 Months of Adjuvant Oxaliplatin + Fluoropyrimidine - Is There a Difference in 5 yr OS?

FEATURING Louise Connell
  • 387 views
  • July 14, 2020
  • 2
09:21

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Advanced CRC: Should Pembrolizumab Be The New SoC as First-line Therapy in Patients With MSI-H mCRC?

FEATURING Louise Connell
  • 493 views
  • July 14, 2020
  • 2
14:43

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Advanced CRC: Is Recently FDA Approved Encorafenib + Cetuximab a New SoC for Previously Treated BRAF V600E-mutant mCRC? Can T-DXd Be an Option for HER2+ Disease?

FEATURING Louise Connell
  • 182 views
  • July 14, 2020
  • 1
12:38

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Pancreatic Cancer Update: Does Gemcitabine + Nab-paclitaxel Improve Complete Pathologic Response in Resectable Disease?

FEATURING Caio Rocha Lima
  • 249 views
  • July 14, 2020
  • 1
08:03

2020 ASCO Virtual Direct™ Highlights

2020 ASCO HCC Update: Is Tremelimumab + Durvalumab Effective, Tolerable, and Biologically Active in Advanced Disease?

FEATURING Caio Rocha Lima
  • 104 views
  • July 14, 2020
11:08

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Gastric & Esophageal: Does the Addition of Pertuzumab/Trastuzumab to FLOT Improve PCR? Can Ramucirumab + FLOT Improve R0 Resection?

FEATURING Caio Rocha Lima
  • 136 views
  • July 14, 2020
  • 1
07:56

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Aggressive B-cell Lymphoma Highlights: Role of a Venetoclax Addition to da-EPOCH-R in 1L DLBCL and Richter’s Transformation. What Do We Do With a PR After 2nd Line Chemo for DLBCL?

FEATURING Jake Soumerai
  • 115 views
  • July 22, 2020
13:05

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Low-grade Lymphoma Highlights: Is CD19 CAR-T Axi-cel Active in R/R Indolent NHLs? Does BOVen (Zanubrutinib, Obinutuzumab, Venetoclax) Achieve Frequent uMRD in 1L CLL? Is 2nd Generation BTKi Zanubrutinib Better Than Ibrutinib in WM?

FEATURING Jake Soumerai
  • 559 views
  • July 22, 2020
  • 5
03:26

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Hodgkin Lymphoma: PD-1 mAb or Brentuximab Vedotin - Which Is the First Option for R/R HL?

FEATURING Jake Soumerai
  • 9 views
  • July 27, 2020
10:08

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on AML: Does Enasidenib + Azacitidine Significantly Improve Responses in Newly Diagnosed IDH2-mutated AML?

FEATURING Tapan Kadia
  • 136 views
  • July 22, 2020
08:39

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on AML: Is Ivosidenib + BCL2 Inhibitor Venetoclax +/- Azacitidine Effective for Patients With IDH1-Mutated AML?

FEATURING Tapan Kadia
  • 191 views
  • July 22, 2020
  • 2
05:04

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on AML: Does Venetoclax Added to Intensive Chemo + CLIA Achieve High Rates of Durable Complete Remission and Low MRD Rates in Pts With Newly Diagnosed AML?

FEATURING Tapan Kadia
  • 228 views
  • July 22, 2020
  • 2
05:12

2020 ASCO Virtual Direct™ Highlights

ASCO Update on CML: What Is the Optimal Ponatinib Dosing in Chronic Phase CML?

FEATURING Tapan Kadia
  • 81 views
  • July 22, 2020
06:05

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on AML: What Is the Optimal Dosing for AMG 330 Dose-escalation Strategy in R/R AML?

FEATURING Tapan Kadia
  • 103 views
  • July 22, 2020
15:07

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Ovarian Cancer Update: Does Maintenance Olaparib Provide an Unprecedented OS Improvement in Relapsed, High-grade Serous or Endometrioid Disease?

FEATURING Rebecca Stone
  • 102 views
  • July 16, 2020
06:05

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Ovarian Cancer Update: Efficacy Analysis of Non-chemo Options for Platinum Sensitive Relapse

FEATURING Rebecca Stone
  • 705 views
  • July 16, 2020
  • 1
09:00

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Improvements in Endometrial Cancer: Single Agent IO in “Non-biomarker” Selected Patients, Cabozantinib + Nivolumab in Advanced Recurrent Metastatic Disease, anti-HER-2 in Advanced or Recurrent Uterine Serous Carcinoma

FEATURING Rebecca Stone
  • 42 views
  • July 16, 2020
04:31

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Cervical Cancer Update: What Is the Long-term Oncological Safety of Sentinel Lymph Node Biopsy in Early-stage Cervical Cancer?

FEATURING Rebecca Stone
  • 17 views
  • July 16, 2020
13:45

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Neoadjuvant Therapy in HR+ BC: Fulvestrant / Fulvestrant + Anastrozole vs. Anastrozole - Was There Significant Improvement of Endocrine-sensitive Disease Rate?

FEATURING Aditya Bardia
  • 299 views
  • July 8, 2020
  • 2
11:45

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Adjuvant Therapy in BC: Is There a Long-term Benefit of MammaPrint as Guidance for Chemo? Does Trastuzumab + Pertuzumab + Chemotherapy Remain SoC for High-risk HER2+ EBC?

FEATURING Aditya Bardia
  • 462 views
  • July 8, 2020
  • 2
04:45

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on MBC: Does Early Local Therapy Improve Survival in Patients With De Novo MBC and an Intact Primary Tumor?

FEATURING Aditya Bardia
  • 22 views
  • July 8, 2020
19:03

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on HER2+ MBC: Comparing Efficacy of HER2 Kinase Inhibitors vs. Antibody Drug Conjugates vs. Immunomodulatory Agents

FEATURING Ian Krop
  • 562 views
  • July 13, 2020
  • 1
14:46

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on TNBC & HR+ MBC: Analysis & Comparison of 1st Line Options for PD-L1 +/- Cancers With(out) BRCA 1/2. Exploring the Optimal ET Agent to Combine With Palbociclib in the First-line Endocrine-sensitive Disease

FEATURING Ian Krop
  • 695 views
  • July 13, 2020
  • 4
12:59

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on HER2+ Neoadjuvant BC: Which Pts Are Candidates for Preoperative Systemic Therapy in Early Stage Setting? Is Therapy With Anthracyclines Inevitable? How Can We Shorten Duration Trastuzumab?

FEATURING Reshma L. Mahtani
  • 13 views
  • July 13, 2020
15:17

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Adjuvant Therapy in HER2+ BC: Utilizing T-DM1 for Pts With Residual Disease vs. Extending Adjuvant Therapy With 1 yr of Neratinib vs. Adding Pertuzumab + SoC Trastuzumab - Which Option Provides Better Results?

FEATURING Reshma L. Mahtani
  • 14 views
  • July 13, 2020
09:30

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on HER2+ MBC: Tucatinib vs. TD-M1 vs. Neratinib - Which Recently FDA Approved Agent Is the Best Option for Sequencing With Existing Therapies?

FEATURING Reshma L. Mahtani
  • 172 views
  • July 13, 2020
  • 1
13:29

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Diagnostic/Prognostic Testing in PC: Is 68Ga- PSMA-11 PET More Accurate for Detection of N1 vs. Histopathology at Time of RP? Is 18F-DCFPyL PET/CT More Sensitive for Detection of Recurrent Disease vs. Standard Imaging Agents?

FEATURING William Kelly
  • 96 views
  • July 15, 2020
05:17

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on mCRPC: Is 177Lu-PSMA-617 Superior PSA Response Rate vs. Cabazitaxel Practice Changing?

FEATURING William Kelly
  • 84 views
  • July 15, 2020
10:14

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Advanced Prostate Cancer: Is Testosterone Suppression With an Oral GnRH Antagonist Relugolix Comparable to Leuprolide?

FEATURING William Kelly
  • 452 views
  • July 15, 2020
  • 4
17:12

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on mUC: Does Switch Maintenance Avelumab + BSC Prolong OS in Patients Who Achieved a Response or Stable Disease to a First-line Platinum-based Chemotherapy?

FEATURING Joseph Kim
  • 219 views
  • July 15, 2020
08:55

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Advanced RCC: Pembrolizumab + Axitinib vs. Sunitinib - Is IO Combination Continuing to Demonstrate Clinical Efficacy?

FEATURING Joseph Kim
  • 88 views
  • July 15, 2020
07:08

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Advanced RCC: Efficacy and Safety Analysis of Nivolumab Monotherapy vs. Nivolumab + Ipilimumab in Treatment-naive Patients

FEATURING Joseph Kim
  • 79 views
  • July 15, 2020
06:56

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Stage III Melanoma: Does Pembrolizumab Improve Recurrence-free Survival After Complete Resection of High-risk Disease?

FEATURING William Sharfman
  • 64 views
  • July 17, 2020
06:53

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Resected Stage III BRAF V600-mutant Melanoma: Is Dabrafenib + Trametinib an Effective Adjuvant Therapy Following Surgery With an Excellent Safety Profile?

FEATURING William Sharfman
  • 32 views
  • July 17, 2020
09:16

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Melanoma: Is There Significant Antitumor Activity for Low-dose Ipilimumab + Pembrolizumab Immediately Following Progression on PD-1 Ab in Melanoma?

FEATURING William Sharfman
  • 32 views
  • July 17, 2020
10:12

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Melanoma: Does Ipilimumab + PD-1 Have a Higher RR and OS vs. Ipilimumab Alone in Patients Resistant to PD-1?

FEATURING William Sharfman
  • 36 views
  • July 17, 2020
08:08

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Stage IV Melanoma: Is Lifileucel Effective and Does it Provide a Durable Response in Patients With High Baseline Disease Burden Who Progressed on Multiple Prior Therapies?

FEATURING William Sharfman
  • 107 views
  • July 17, 2020
18:53

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on 1L Treatment of ES-SCLC: IO + Chemo - Results from KEYNOTE-064 Study (Pembro + EP Improve PFS) & CASPIAN Study (Durvalumab + EP new SoC)

FEATURING Nagashree Seetharamu
  • 249 views
  • July 10, 2020
10:35

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on NSCLC: Neoadjuvant Chemo for Locally Advanced Disease, Gefitinib vs Chemo for EGFR+ NSCLC & Adjuvant Osimertinib ‘Practice Changing’ for Early-Stage EGFR Mutated NSCLC

FEATURING Nagashree Seetharamu
  • 89 views
  • July 15, 2020
22:55

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on 1st Line IO Strategies for Metastatic NSCLC: Should CheckMate 227 (Ipi + Nivo) and CheckMate 9LA (Nivo/Ipi + Chemo) Data Change My Practice? Tiragolumab/Atezolizumab Shows Promising Activity in PD-L1+ NSCLC

FEATURING Ibiayi Dagogo-Jack
  • 734 views
  • July 13, 2020
  • 1